SciBase receives additional Castle Biosciences order
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The order strengthens SciBase's revenue pipeline and validates its collaboration with Castle Biosciences, potentially boosting investor confidence in SciBase's growth prospects. For Castle Biosciences, the order advances its clinical development efforts in dermatology, supporting its strategic initiatives.
SciBase Holding AB announced on September 8, 2026 that it received an additional order from Castle Biosciences under their ongoing collaboration. The order, valued at approximately $0.6 million (MSEK 5), includes the portable Nevisense Go pen device and electrodes. It will accelerate the current clinical study on predicting relapses in atopic dermatitis and support preparations for a second clinical study. Deliveries are expected to start in Q4 2026. This order follows the collaboration and license agreement signed in 2025 and signals the expansion of the partnership.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard